IDO1 and neoplasm: Our assays suggest an additional benefit of inhibiting the STAT3/IDO1 axis in resistant cells, i.e. the restoration of a significant expansion of T-lymphocytes that would be otherwise suppressed in the presence of multidrug resistant tumor cells.